Showing results (121-130 of 130) with videos related to
Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 130 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2022
Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell CarcinomaAndrey A Yurchenko, Oltin T Pop, Meriem Ighilahriz, et al.Oncoimmunology|December 3, 2021
Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survivalFiamma Berner, Rebekka Niederer, Jolien J Luimstra, et al.Science Immunology|September 2, 2022
Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockadeFiamma Berner, David Bomze, Christa Lichtensteiger, et al.Journal for Immunotherapy of Cancer|May 14, 2021
Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort studyNikolaus B Wagner, Max M Lenders, Kathrin Kühl, et al.Med (New York, N.Y.)|January 24, 2023
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitorsNicolas Gonzalo Nuñez, Fiamma Berner, Ekaterina Friebel, et al.American Journal of Respiratory and Critical Care Medicine|April 16, 2024
Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint BlockadeNina Wyss, Fiamma Berner, Vincent Walter, et al.American Journal of Respiratory and Critical Care Medicine|August 4, 2022
Pulmonary Surfactant Proteins Are Inhibited by Immunoglobulin A Autoantibodies in Severe COVID-19Tobias Sinnberg, Christa Lichtensteiger, Omar Hasan Ali, et al.The New England Journal of Medicine|June 2, 2025
Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell CarcinomaDanny Rischin, Sandro Porceddu, Fiona Day, et al.Journal of the American Academy of Dermatology|September 8, 2024
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6Brett G M Hughes, Alexander Guminski, Samantha Bowyer, et al.Immunity|October 14, 2020
CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T CellsMatthias Braun, Amelia Roman Aguilera, Ashmitha Sundarrajan, et al.Pageof 13